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Abstract: Hormonal deprivation therapy is well established for the treatment of locally 
advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients 
with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have 
become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and 
convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are 
well established and widely used to this end. Recently, a 6-month depot leuprorelin has been 
approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and 
side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment 
option for these patients. This review will highlight the role of GnRH agonists in the treatment 
of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused 
outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available 
shorter-acting products.
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Prostate cancer is one of the leading causes of cancer deaths among men in the 
United States. Current treatment options include radical prostatectomy, external beam 
radiotherapy, brachytherapy, and hormonal therapy. Hormonal therapy has become 
a mainstay of palliative treatment for patients with locally advanced or metastatic 
disease. Additionally, androgen deprivation is sometimes integrated with radiotherapy 
as definitive treatment of patients with localized disease. Selection factors for treatment 
include patient factors such as age, comorbidities, and patient preference; disease 
characteristics such as prostate-specific antigen (PSA), Gleason score, and stage; and 
psychosocial factors such as sexual function. Long-acting gonadotropin releasing 
hormone (GnRH) agonists have become widely accepted among patients and physicians 
as an alternative to earlier androgen-deprivation strategies, which included surgical 
castration and daily GnRH injections. Depot formulations of 1-month, 3-month, and 
4-month dosages are well-established in the treatment of prostate cancer. This review 
will outline the role of hormonal deprivation therapy for prostate cancer patients, 
with an emphasis on the pharmacologic and clinical profile of a new 6-month depot 
formulation of leuprorelin acetate, also known as leuprolide acetate.
Therapeutic indications
Androgen suppression therapy is utilized as single-modality therapy for patients with 
localized disease as well as in conjunction with radiotherapy in patients with locally Clinical Interventions in Aging 2009:4 260
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advanced disease or intermediate to high risk localized 
disease.
The rationale for using androgen deprivation with 
radiation therapy is based on the principle that cytoreduction 
through 2 modalities, namely hormones and radiation, may 
be more effective than local therapy alone. Movement toward 
this therapy began in patients with adverse tumor features 
such as bulky tumors, high PSA, and high Gleason score 
since they carried a poor prognosis with radiation therapy 
alone. Androgen suppression therapy is usually given in a 
neoadjuvant and concurrent manner, with additional adjuvant 
treatment following radiotherapy in those patients requiring 
longer-term treatment.
Neoadjuvant hormonal therapy could theoretically improve 
tumor control through 3 mechanisms: (1) Cytoreduction of 
tumor volume through apoptosis, (2) enhanced tumor cell kill 
because of radiation induced damage that leads to alternative 
pathways for apoptosis, or (3) improved radiosensitivity 
through reduced intra-tumoral hypoxia. While it is unclear 
which mechanism is most active, the cytoreductive 
mechanism is most strongly supported by in vitro and in vivo 
animal experiments and clinical investigations.1
Multiple randomized-controlled trials have compared 
clinical outcomes of radiotherapy with adjuvant hormonal 
therapy to radiotherapy alone in prostate cancer patients with 
localized and locally advanced disease as well as patients 
with regional nodal involvement.2–11 A meta-analysis of five 
consecutive Radiation Therapy Oncology Group (RTOG) 
phase III trials, including 2742 men treated between 1975 and 
1992 showed improved outcomes in some groups of patients 
who received hormonal deprivation therapy. Patients were 
stratified into four prognostic risk groups based on Gleason 
score, clinical T-stage, and pelvic nodal involvement. PSA 
was not included because most patients were treated in 
the pre-PSA era. While low-risk patients (Gleason score 
2–6 and T1–2Nx) did not benefit from adjuvant hormonal 
therapy, the intermediate- and high-risk groups (T3, N+, or 
Gleason score  6) had improved overall survival and 8-year 
disease-specific survival with the addition of long-term 
hormonal therapy.12–13 In the intermediate- and high-risk 
groups, 8-year overall survival improved from 45% to 61% 
and 28% to 44%, respectively, and 8-year disease-specific 
survival improved from 70% to 88% and 42% to 69%, 
respectively, when long-term hormonal therapy was used.
Many investigators have adopted a combined neoadjuvant-
concurrent-adjuvant approach to hormonal therapy. D’Amico 
and colleagues conducted a prospective randomized trial in 
intermediate- and high-risk patients. Patients had localized 
disease but were required to have at least one adverse feature, 
defined as a PSA of greater than 10, a Gleason score of greater 
than 7, or radiographic evidence of extraprostatic disease 
on magnetic resonance imaging. Intermediate-risk patients 
were those with a Gleason score of 7 and PSA  20 or with 
PSA 10–20 and Gleason  6. Patients were randomized to 
either radiation therapy alone to a dose of 70 Gy in 7 weeks 
to a localized prostate volume versus the same radiotherapy 
with 6 months of androgen suppression which was started 
2 months before radiation and continued during radiation and 
then for 2 months after radiation. With a median follow-up 
of 4.5 years, the authors observed a significantly higher 
survival (88% vs 78% at 5 years), lower prostate cancer 
specific mortality (3.8% versus 0% at 5 years), and higher 
survival free of salvage androgen suppressive therapy (82% 
vs 57% at 5 years).14
The timing and duration of androgen deprivation are 
still debatable topics, but many investigators believe 
that 6 months of androgen deprivation is appropriate for 
intermediate-risk cases while a longer duration (2 to 3 years) 
is more appropriate for patients with high-risk disease. This 
neoadjuvant-concurrent-adjuvant approach has also been 
adopted for longer-term androgen deprivation. Current 
studies in the RTOG typically employ 2 months of hormone 
treatment prior to RT and then continue for a total of 2 years 
in high risk patients. Ongoing studies are also examining 
whether shorter durations of hormonal therapy will suffice 
since androgen deprivation can confer significant toxicity.
Androgens and the prostate
Testicular hormone secretion has long been known to influence 
prostate growth. In the 18th century, surgical castration was 
noted to cause prostate atrophy in adult animals and halt 
prostate growth in younger animals.15 In the late 19th century, 
castration was utilized to treat urinary retention caused by 
prostatic hyperplasia. In one early case series published in 
1895, over half of the patients experienced improvement of 
urinary symptoms after surgical castration.16
Androgen deprivation therapy (ADT) was first proposed 
as a treatment for prostate cancer in 1940 when castration 
was utilized to provide pain relief, stabilize tumor burden, 
and reduce serum acid phosphatase in prostate cancer patients 
with osseous metastatic tumors.17,18
Given the morbidity of surgical orchiectomy and 
associated clinical side effects, alternative anti-androgenic 
measures have been sought. One early approach attempted 
chemical castration through injection of the female hormones 
stilbestrol and hexestrol to neutralize the effect of testicular Clinical Interventions in Aging 2009:4 261
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androgens.18 The mechanism of this effect was discovered 
many years later: estrogen inhibits hypothalamic GnRH 
release through a negative feedback mechanism.19
In subsequent decades, the role of the hypothalamic-
pituitary axis in controlling testosterone production, namely 
through the secretion of GnRH, was elucidated. GnRH 
is secreted in a pulsatile fashion by the hypothalamus. 
This stimulates the anterior pituitary gland to release 
gonadotropin, which in turn acts on Leydig cells within the 
testes to stimulate testosterone production. Testosterone and 
adrenal androgens can be converted to dihydrotestosterone 
(DHT), a more potent hormone, within the cytoplasm of 
prostatic cells by the enzyme 5-alfa-reductase.20 DHT binds 
to an androgen receptor within the cytosol, then translocates 
into the nucleus where it can affect gene synthesis, the 
production of proteins such as prostate-specific antigen 
(PSA), and cellular functions such as proliferation, growth, 
and cell death.
In subsequent years, multiple classes of anti-androgenic 
drugs have been developed to target the different steps of 
elucidated androgen regulatory pathways. These drug classes 
include GnRH agonists, GnRH antagonists, anti-androgens, 
5-alfa reductase inhibitors, and the antifungal agent 
ketoconazole.21–23 In clinical practice, synthetic GnRH 
agonists, especially in depot formulations, remain the 
mainstay of hormonal ablative therapy.
Currently available leuprorelin 
formulations
In 1971, GnRH was first isolated and characterized in the 
laboratory.24 Leuprorelin, a synthetic analogue of GnRH, was 
first synthesized for clinical use in 1974.25 Leuprorelin has 
a longer half-life and is 80 times more potent than naturally 
occurring GnRH, because of its enhanced binding affinity 
and increased resistance to degradation by peptidases.26 
Alterations in the chemical structure, including substitution 
of a D-amino acid for glycine at position 6 and deletion of 
glycine at position 10 with the insertion of ethylamide, are 
responsible for these properties.27
The clinical benefits of GnRH analogues in prostate 
cancer patients were first described by Tolis et al in 1982. Ten 
patients with locally advanced or metastatic prostate cancer 
were treated with leuprorelin given as daily subcutaneous 
injections or twice daily intranasal applications for a period 
of 6 weeks to 12 months. During the treatment period, those 
patients with urinary obstruction noted improvement in urine 
flow, and those with osseous metastases reported decreased 
bone pain.28
In 1985, leuprorelin was approved by the US Food and 
Drug Administration (FDA) for the palliative treatment of 
advanced prostate cancer.29 Although the first clinical uses 
of synthetic GnRH required cumbersome daily injections, 
usually 1 mg given subcutaneously or intramuscularly, 
development of this medication revolutionized hormonal 
ablation therapy by allowing men to avoid the psychological 
and emotional consequences of surgical castration.
Technological advances have fostered the development 
of multiple long-acting depot formulations of GnRH in 
order to improve convenience of use, quality of life, and 
patient compliance. The first long-acting formulation was a 
monthly injection approved by the FDA in 1989 for treatment 
of advanced prostate cancer.30 In the US, leuprorelin is 
now available in monthly (7.5 mg), 3-monthly (22.5 mg), 
4-monthly (30 mg), and 6-monthly (45 mg) dosages.
The 3-monthly and 4-monthly formulations were approved 
by the FDA in 2002 and 2003, respectively, for treatment 
of advanced prostate cancer. They gained wide popularity, 
and within a year of its release, the 4-monthly formulation 
accounted for 40% of the market.31 Most recently, the FDA 
approved a 45 mg 6-month depot leuprorelin in December 
2004 for the palliative treatment of locally advanced or 
metastatic prostate cancer. These long-acting formulations 
are easy to use and require less effort on the part of both 
patient and clinician, which may in turn improve patient 
compliance, clinical efficacy, and outcomes. Additionally, 
unlike surgical castration, these medications are reversible, 
which can protect patients from the long-term consequences 
of a hypo-androgenic state such as osteopenia and muscle 
atrophy.
In Europe, a 3.75 mg 1-month depot leuprorelin 
formulation and an 11.25 mg 3-month depot formulation 
are available for prostate cancer treatment. In the US, 
these dosages are FDA approved only for the treatment of 
endometriosis, fibroids, and precocious puberty, but not 
for the treatment of prostate cancer. A 6-monthly 30 mg 
leuprorelin dosage has been developed and tested for 
efficacy and clinical safety in a recent European multicenter 
prospective trial.32
Sustained release parenteral depot formulations 
administer hydrophilic leuprorelin that has been entrapped 
in biodegradable, highly lipophilic synthetic polymer 
microspheres. The preparation is made by dissolving both the 
drug and the biodegradable polymer in an organic solvent, 
with resultant in situ microsphere formation. Leuprorelin is 
released from the microspheres at a functionally constant rate 
over 1, 3, 4, or 6 months, depending on the polymer type.33,34 Clinical Interventions in Aging 2009:4 262
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The delivery system for the six-month depot formulation 
utilizes a DL-lactide-co-glycolide polymer, with an 85:15 
DL-lactide to glycolide molar ratio.
A12-month subcutaneous implant was developed and 
briefly available for clinical use after approval by the FDA 
in 2000 for treatment of locally advanced or metastatic 
prostate cancer. However, the drug did not gain popularity 
and was eventually discontinued by the manufacturer in 
December 2007.35,36 There may have been less interest in 
this formulation compared to the depot injections because 
the 12-month implant entailed a surgical procedure for 
administration and required good follow-up with patient 
return for implant removal 12 months later.
Mode of action
Leuprorelin, is a synthetic nonapeptide analogue of 
naturally occurring GnRH. The chemical name is 5-oxo-L-
prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-
L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt).37
When given continuously, leuprorelin inhibits pituitary 
secretion of gonadotropin, which in turn suppresses testicular 
and ovarian steroidogenesis. Initial administration of 
leuprorelin causes an increase in gonadotropin levels, which 
can last for several weeks, leading to a rise in gonadal steroid 
production during that time. With continuous administration, 
there is eventual suppression of gonadotropin release within 
2 to 4 weeks. In males, testosterone is reduced to a level 
below the castrate threshold, or 50 ng/dL. Upon removal 
of the drug, this effect is reversible.33
Pharmacokinetics of leuprorelin 
depot
Because it is a peptide, leuprorelin is not active when given 
orally and is usually administered through a subcutaneous 
or intramuscular route.
Pharmacokinetic studies showed that mean peak plasma 
leuprorelin concentrations (Cmax) were 13.1, 21.8, 47.4, 
54.5 and 53 µg/L after injection of 3.75, 7.5, 11.25, 15, and 
30 mg depot formulations, respectively, and occurred within 
1 to 3 hours of administration. After subcutaneous injection of 
1 mg of a non-depot formulation, mean Cmax was 35 µg/L and 
occurred 36 to 60 minutes after injection.39 Following injection 
of 45 mg 6-month depot formulation, there was an early rise 
in Cmax to 82.0 ng/mL 4.5 hours after the initial administration. 
On the second injection, 6 months after the initial treatment, 
mean Cmax was 102 ng/mL and occurred 4.5 hours after the 
second injection. After these initial increases, mean serum 
levels remained constant within the 0.2 to 2 ng/mL range.37
The mean volume of distribution of leuprolide after 
bolus administration in a group of healthy male volunteers 
was 27 L.39 After a single subcutaneous injection of 1 mg, 
3.75 mg, 7.5 mg, or 15 mg leuprorelin, the mean volumes of 
distribution were 36 L, 33 L, and 27 L, respectively.
Total body clearance and elimination half-life were 
9.1 L/hour and 3.6 hours, respectively, after a 1 mg 
subcutaneous administration. After intravenous bolus, these 
values were 8.3 L/hour and 2.9 hours, respectively.33
To our knowledge, there is no published data documenting 
the volume of distribution, elimination half-life, or clearance 
of the 45 mg 6-month depot formulation of leuprorelin. The 
pharmacokinetics of leuprorelin have not been evaluated in 
a population of patients with compromised kidney or liver 
function.
Efficacy
Serum testosterone
The efficacy of the 6-month depot leuprorelin formulation 
was evaluated in a 12-month, open label, multicenter trial. 
One hundred eleven patients with prostate adenocarcinoma 
were enrolled. Inclusion criteria were stage  T1, WHO 
performance score 0–2, and life expectancy 1 year. Patients 
received leuprorelin 45 mg subcutaneously on days 1 and 168, 
a six month interval.38 The primary endpoint of this study 
was a decrease in serum testosterone to a level equivalent 
to or below that resulting from surgical castration. Histori-
cally, the FDA had established the castrate threshold, or the 
testosterone level consistent with that obtained after surgical 
orchiectomy, to be 50 ng/dL.41 However, this was largely 
based on the sensitivity of available laboratory assays at 
the time. With the development of newer assay techniques, 
substantially lower testosterone levels (15 ng/dL) have been 
observed in men after bilateral orchiectomy, which has led to 
reassessment of the historical threshold level by the medical 
community. The National Comprehensive Cancer Network 
amended its guidelines to suggest that serum testosterone 
level  20 ng/dL reflected optimal control of testosterone 
after surgical or chemical castration, and several other expert 
opinions have been published on this matter in agreement.41,42 
In light of this, the 6-month depot leuprorelin efficacy study 
evaluated the number of patients with serum testosterone 
level below two separate thresholds: 50 ng/dL and also below 
20 ng/dL, measured on at least two occasions at least 1 week 
apart. Serum PSA and gonadotropin levels and treatment-
related toxicity were also assessed.
One hundred three of the 111 enrolled patients received 
both injections. There was an initial rise in testosterone Clinical Interventions in Aging 2009:4 263
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level, which increased to a mean level of 588 ng/dL by 
day 2. By day 28, 108 patients (97%) had achieved a 
serum testosterone level at or below the castrate threshold 
(50 ng/dL), and 92 (83%) had achieved optimal control of 
testosterone (20 ng/dL). After 12 months, 102 of the 103 
(99%) patients who completed the study had testosterone 
levels below castrate threshold, and 91 patients (88%) had 
optimal control of testosterone. Median time to reach castrate 
level was 21 days.
One patient did not experience castrate level androgen 
suppression and was removed from the study at day 85. During 
a follow-up period of 12 months, only 1 patient experienced 
breakthrough testosterone levels above 50 ng/dL.38
In comparison to conventional GnRH agonists, clinical 
studies indicate that 6-month depot leuprorelin may be more 
efficacious, although there are no prospective trials comparing 
these different formulations. Five percent to 17% of patients 
treated with daily GnRH injections do not reach the historical 
castrate level (50 ng/dL), and 13% to 34% fail to achieve 
optimal control of testosterone (20 ng/dL).40,43–47
Six-month depot leuprorelin appears to have similar 
efficacy to the other available depot formulations. The 
proportion of patients achieving optimal testosterone control 
(20 ng/dL) after 6 to 8 months of treatment with 6-monthly 
(45 mg), 4-monthly (30 mg), 3-monthly (22.5 mg), and 
monthly (7.5 mg) formulations were 94%, 90%, 97.5%, and 
94%, respectively.48–50 Among the different formulations, 
98% tp 100% of patients who completed the study had 
castrate level serum testosterone at study completion.
Transient testosterone escape (level  50 ng/dL on two 
separate occasions at least a week apart) was observed in 
no patients treated with the 7.5 mg monthly or 22.5 mg 
3-monthly formulations. Three patients treated with the 
30 mg 4-monthly formulation had transient testosterone 
breakthrough at 4 months, and 1 of these patients had a 
second breakthrough at 8 months. This patient had a small 
but clinically insignificant rise in PSA from 2.2 to 2.6 during 
the first breakthrough response but did not exhibit any other 
PSA elevations during treatment. One patient treated with 
the 45 mg 6-monthly formulation had transient testosterone 
breakthrough.38,48–50
Testosterone breakthrough is seen in about 5% of patients 
treated with conventional, daily leuprorelin injections.40 
There are several theories to explain this phenomenon, 
including increased GnRH receptor density during treatment, 
alternate GnRH receptor expression, phosphorylation of the 
GnRH receptor or its downstream G-protein, and uncoupling 
of the GnRH receptor and its target G-protein.51
A recent European multicenter, prospective randomized 
trial compared treatment of prostate cancer patients over 
12 months with an 11.25 mg 3-monthly formulation (currently 
approved for use in Europe), with two different 6-month 
depot formulations: a 22.5 mg dose and a 30 mg dose. One 
hundred seventy-eight patients with newly diagnosed or 
relapsed prostate cancer of any grade or stage were enrolled 
in the trial. Because of inferior response rates and efficacy of 
the 22.5 mg 6-month depot formulation, it was not selected 
for submission for approval in European countries, and 
therefore results from that arm were not published. The 
remaining two arms had similar efficacy and safety profile. 
After 12 months of treatment, 100% versus 98% of patients 
treated with 11.25 mg 3-month depot and 30 mg 6-month 
depot leuprorelin, respectively, had serum testosterone levels 
below castrate level (50 ng/dL), and 90% versus 81% had 
optimal testosterone control (20 ng/dL), respectively. 
These differences were not statistically significant.38 As a 
result of this study, the 30 mg 6-month depot formulation 
has been submitted for approval for use in the treatment of 
prostate cancer patients in Europe.
Several recent studies indicated that depot leuprorelin 
formulations may be efficacious for longer than the 
recommended dosing intervals. Pathak et al conducted 
a prospective study in which 42 patients were treated 
with 22.5 mg subcutaneous injections of leuprorelin 
every 3 months, on day 1, after 12 weeks, and after 24 weeks. 
Serum testosterone levels were monitored at baseline, after 
12 weeks, after 24 weeks, and monthly thereafter. If patients 
were still at castrate levels after 24 weeks, the subsequent 
injection was withheld until testosterone exceeded 50 ng/dL. 
After a median follow-up of 18 months, the median dosing 
interval was 6 months, with a range of 5 to 12 months.52
A recent prospective trial by Greil et al evaluated this type 
of testosterone-based treatment approach in patients treated 
with the 30 mg 4-month depot leuprorelin formulation. 
Serum testosterone levels were obtained at baseline and 
then monthly beginning 4 months after the first injection and 
2 months after subsequent injections for a total of 18 months. 
The median number of days from injection to the first serum 
testosterone level  50 ng/dL was 159, 189, and 163 days for 
the first, second, and third treatment cycle, respectively.53
A multicenter randomized controlled trial by Gulley et al 
assessed time to testosterone recovery in 159 patients treated 
with two 6-month cycles of GnRH agonist therapy with two 
3-month injections of leuprorelin (22.5 mg) or goserelin, 
another GnRH agonist.54 Serum testosterone, DHT, and 
PSA were measured monthly until serum PSA progressed Clinical Interventions in Aging 2009:4 264
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to a level above 5 ng/mL, at which point a second cycle was 
administered. Median time to testosterone normalization was 
15.4 weeks and 18.3 weeks after cycles 1 and 2 respectively. 
Median time to DHT normalization was 15.2 weeks and 
18.7 weeks after cycles 1 and 2, respectively.
These three studies suggest that patients treated in a 
testosterone-based manner can achieve sustained efficacy 
with exposure to fewer injections and lower drug levels, 
which may improve cost effectiveness and side effect 
profiles of GnRH agonist therapy. Additionally, periodic 
monitoring of serum testosterone levels is an important step 
in identifying patients who fail to achieve castrate levels or 
have breakthrough rises in testosterone while undergoing 
androgen deprivation treatment. For these reasons, some 
physicians are proponents of an individualized approach 
to hormonal deprivation therapy based upon patient serum 
testosterone levels as opposed to simply adhering to 
recommended dosing intervals.
Prostate-specific antigen
In patients treated with 45 mg 6-month depot leuprorelin, 
the percentage of patients with serum PSA levels within the 
normal range (4 ng/mL) at baseline and after treatment 
was 25% and 96%, respectively. Mean PSA at baseline and 
after 12 months of treatment was 39.8 ng/mL and 1.2 ng/mL, 
respectively. This is similar to levels seen in patients treated 
with 7.5 mg monthly, 22.5 mg 3-monthly, and 30 mg 
4-monthly dosages (Table 1).38,48–50
Similar PSA levels were seen in the European randomized-
controlled trial evaluating the lower dose depot formulations, 
including 11.25 mg 3-month depot and 30 mg 6-month depot 
leuprorelin. During months one through 12 of the study, PSA 
levels ranged from 0.2 to 1.0 ng/mL in the 3-monthly group 
and from 0.3 to 1.1 ng/dL in the 6-monthly group.
Serum gonadotropin
In the European multicenter clinical efficacy trial for 
45 mg 6-monthly leuprorelin, there was an initial rise in 
gonadotropin as a result of leuprorelin’s GnRH agonist 
properties. Eight hours after injection with 45 mg depot 
leuprorelin, gonadotropin had increased to a mean of 
37.9 mIU/mL. By day 7, mean gonadotropin decreased 
below baseline (6.9 mIU/mL), and it consistently declined 
over the first 19 weeks to a mean level of 0.1 mIU/mL. After 
the second injection, there was a transient, small increase in 
serum gonadotropin level to 0.2 mIU/mL on day 169, and 
gonadotropin levels remained steady at this level for the 
remainder of the study.38
A similar pattern of gonadotropin surge was seen with 
administration of 7.5 mg monthly, 22.5 mg 3-monthly, and 
30 mg 4-monthly dosages in the respective efficacy trials. 
Peak gonadotropin levels occurred on days 1 or 2 after 
leuprorelin administration, and decreased to below baseline 
between days 10 and 14.
An initial rise in testosterone occurs in parallel with 
this gonadotropin surge. Mean testosterone increased by 
225 ng/dL by day 2, to 588 ng/dL, after the first injection of 
6-month depot leuprorelin. A similar effect was seen with 
the other depot formulations.55,56 No clinically significant 
flare reactions in response to the early testosterone rise have 
been reported.38,48–50
Safety and tolerability
The majority of patients undergoing treatment with depot 
leuprorelin experience mild side effects. Fewer patients 
experience moderate adverse reactions, and severe toxicity is 
rarely reported. The most common side effects of leuprorelin 
are hot flashes, injection site reactions, fatigue, testicular 
atrophy, and gynecomastia.
After treatment with 45 mg 6-month depot leuprorelin, 
82 (74%) of 111 participants reported 211 treatment-related 
side effects. One event was reported as severe, although the 
type of adverse reaction was not documented, and the other 
210 events were mild to moderate.38
Depot leuprorelin 45 mg 6-month has a similar side 
effect profile to the other depot formulations. Fifty-seven 
percent of patients treated with 22.5 mg 3-month depot 
leuprorelin experienced mild side effects, 12% experienced 
moderate side effects, and no patients experienced severe 
side effects.49 Eighty-five percent of patients treated with 
30 mg 4-month depot leuprorelin experienced treatment-
related side effects, with 97% of  these reactions being mild 
to moderate and 3% documented as severe hot flashes.50 
Table 1 effect of depot leuprorelin on serum prostate-specific 
antigen (PSA) level38,48–50
Leuprorelin dosage
7.5 mg 22.5 mg 30 mg 45 mg
Pretreatment
  Mean PSA 32.9 86.4 13.2 39.8
  % patients with PSA 
4 ng/mL
25 27 24 33
end of study
  Mean PSA 1.2 1.7 1.3 3.2
  % patients with PSA 
4 ng/mL
96 93 83 96Clinical Interventions in Aging 2009:4 265
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Seventy-four percent of patients treated with monthly 
depot leuprorelin experienced side effects of treatment. 
Most events were graded as mild to moderate; however 4% 
were considered severe, including hot flashes in 1 case and 
injection site burning in 4 instances.48
Overall, with the exception of a notably higher rate of 
mild injection site reactions documented in patients receiving 
the 22.5 mg dosage, there were no substantial differences 
between the side effect profile of patients treated with the 
different depot formulations (Table 2).
No patients stopped treatment with the 45 mg, 22.5 mg, or 
7.5 mg dosages due to treatment-related side effects. However, 
3% of participants in the 4-month 30 mg depot leuprorelin 
clinical efficacy trial stopped because of side effects of treat-
ment, although the specific reactions that caused patients to 
withdraw from the study were not documented.50
Treatment compliance of patients enrolled in the above 
clinical efficacy trials was good. Of the patients enrolled 
for treatment with 7.5 mg monthly, 22.5 mg 3-monthly, 
30 mg 4-monthly, and 45 mg 6-monthly leuprorelin, 
98%, 98%, 91%, and 93% completed the 1-year treatment 
course, respectively.
In the European randomized controlled trial evaluating 
the lower-dose formulations (11.25 mg 3-month depot and 
30 mg 6-month depot leuprorelin), 4% of patients withdrew 
from the study because of treatment-related adverse events. 
The most common side effects were hot flashes and injection-
site reactions. Hot flashes occurred in 43% versus 34% of 
patients treated with 3-monthly and 6-monthly injections, 
respectively, and injection site reactions occurred in 2% 
and 11% of patients, respectively. About two-thirds of the 
injection site reactions were considered severe.32
In summary, the available depot leuprorelin formulations 
are convenient and well tolerated with acceptable side 
effect profiles. Severe adverse events are rare, and 
patient compliance within published clinical studies 
is good. Few patients withdrew from the trials because 
of treatment-related side effects, and over 90% of patients 
completed the treatment course.
Conclusions
Hormonal deprivation therapy has become the mainstay 
of treatment for locally advanced and metastatic prostate 
cancer, as well as for the adjuvant treatment of patients 
with intermediate-risk or high-risk localized prostate cancer. 
Androgen deprivation has been shown to improve quality of 
life and prolong life in many patients who fall within these 
categories.
Surgical castration was the earliest form of androgen 
deprivation, but this has been replaced by chemical agents, 
which potentially have less physical and emotional impact 
than the surgical alternative. GnRH agonists are potent agents 
that block testosterone secretion from the testes, which 
encompasses 90% of the body’s testosterone production.31 
While the first synthetic GnRH analogues required daily 
injections, the introduction of long-acting synthetic GnRH 
agonists in the 1980s and 1990s revolutionized the hormonal 
treatment of prostate cancer. With their ease of use, tolerable 
side effect profile, and good efficacy, the depot formulations 
have gained wide acceptance from both patients and the 
medical community alike.
Today, 3-month and 4-month depot leuprorelin 
formulations are the most commonly used hormonal agents 
for the treatment of prostate cancer. Treatment with the 
shorter-acting variations such as 1-month depot and daily 
formulations presents more opportunities for patients 
to delay or altogether miss treatments, which can result 
in testosterone breakthrough and potentially deleterious 
effects on tumor control and symptom progression. The 
longer-acting formulations offer clinical benefit on these 
fronts by limiting the number of treatments involved in a 
therapeutic course.
Table 2 Treatment-related adverse events of 6-month (45 mg), 4-month (30 mg), 3-month (22.5) mg, and 1-month (7.5 mg) depot 
leuprorelin38,48–50
Leuprorelin dose
Adverse event:  
Mild – Moderate – Severe (%)
45 mg 30 mg 22.5 mg 7.5 mg
Hot flashes 33–24–0 59–18–2 49–10–0 44–12–1
Injection site reaction 14–1–0 22–0–0 89–14–0 29–4–1
Fatigue 7–5–0 10–4–0 6–0–0 13–4–0
Testicular atrophy 5–2–0 4–0–0 2–0–0 4–1–0
Gynecomastia 4–0–0 2–0–0 1–0–0 1–1–0Clinical Interventions in Aging 2009:4 266
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The most recent addition to the hormonal deprivation 
armament is the 45 mg 6-month depot leuprorelin formulation. 
Further reducing the number of injections patients receive 
presents a number of advantages. First, treatment compliance 
will likely be improved with a decreased number of 
therapeutic delays or misses resulting in testosterone 
breakthrough. Second, patients may have fewer clinic visits, 
which are often anxiety-ridden and disruptive to their daily 
routine. Finally, since burning at the injection site is one 
of the most commonly reported treatment-related adverse 
events, the longer-acting formulations may improve the 
overall tolerability of the treatment by exposing patients to 
fewer injections.
In the US, multiple long-acting depot products (7.5 mg 
monthly, 22.5 mg 3-monthly, 30 mg 4-monthly, and 45 mg 
6-monthly formulations) have been approved for use in 
prostate cancer. In Europe, several additional, lower-dose 
depot products have been approved for treatment of prostate 
cancer patients, including 3.75 mg monthly and 11.25 mg 
3-monthly formulations.
Two clinical trials have shown that testosterone is often 
suppressed for longer than the recommended interval for 
a given depot product.52,53 Therefore, some physicians 
are proponents of an individualized, testosterone-based 
treatment system that utilizes periodic evaluation of serum 
testosterone levels to guide injection intervals and to detect 
non-responders and testosterone breakthrough.
In clinical trials thus far, 45 mg 6-month depot leuprorelin 
has similar clinical efficacy and tolerability, with acceptable 
rates of mild side effects and low rates of moderate to severe 
adverse events, compared with preceding shorter-acting 
depot formulations. The associated benefits of improved 
convenience, compliance, and tolerability will likely make 
this formulation popular among physicians and patients alike 
within the coming years.
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